DBV Technologies reported $136.76M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 167.36M 167.35M Jun/2025
Alnylam Pharmaceuticals USD 130.98M 129.67M Jun/2025
Amarin USD 308.15M 2.85M Mar/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
DBV Technologies USD 136.76M 125.11M Jun/2025
Halozyme Therapeutics USD 117.62M 117.5M Jun/2025
Incyte USD 194.12M 193.93M Jun/2025
Insmed USD 211.11M 209.29M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
PTC Therapeutics USD 79.38M 79.3M Jun/2025
Sarepta Therapeutics USD 97.71M 97.7M Jun/2025
Ultragenyx Pharmaceutical USD 96.35M 2.45M Jun/2025
United Therapeutics USD 45.22M 44.42M Jun/2025